Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone vs. Observation in HER2-Negative Breast Cancer with Residual Disease
NCT00877500Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2009
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixabepilone in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2009; status: active, not recruiting.
02
Drugs
ixabepilone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00877500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00877500.